Hymecromone is under clinical development by Halo Biosciences and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). According to GlobalData, Phase II drugs for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Hymecromone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hymecromone overview

Hymecromone is under development for the treatment of pulmonary hypertension (PH) including interstitial lung disease and primary sclerosing cholangitis. It is administered by oral route. The drug candidate acts by targeting hyaluronan. It was also under development for type I diabetes.

Halo Biosciences overview

Halo Biosciences is centered around making first-in-class, illness changing treatments utilizing creative ways to deal with alter the extracellular lattice (ECM). It is headquartered in Stanford, California, the US.

For a complete picture of Hymecromone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.